Rohan Garje, MD, Miami Cancer Institute, provides an overview of his comparison of survival outcomes of sarcomatoid urothelial carcinoma versus classic urothelial carcinoma in patients with T2-T4, N0-N1 bladder cancer after definitive therapy.
Dr. Garje on Survival Outcomes of Sarcomatoid Versus Classic Urothelial Carcinoma of Bladder
By Rohan Garje, MD - Last Updated: June 4, 2023Related Posts
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.